Skip to content

Dr Joachim Feldges



Feldges Joachim
Dr Joachim Feldges



Joachim is a highly renowned patent litigator. He has practised complex patent litigation since more than 34 years with a particular focus on pharmaceuticals, biotechnology and medical devices. He represents clients in infringement and validity cases before all major patent courts, the Federal Supreme Court and the Federal Patent Court and he has advised clients for many years developing and implementing international patent litigation strategies in numerous European jurisdictions.

In addition, Joachim regularly represents clients in opposition proceedings before the European Patent Office. He also has advised on various global and regional technology transfer agreements has had frequent involvement in dispute resolution regarding such agreements. He also represents clients in arbitration proceedings and acts as an arbitrator and mediator according to WIPO rules as well as other statutes in IP disputes. Joachim is a member of the WIPO Advisory Committee on Arbitration and Mediation. In particular, he is listed as an arbitrator at WIPO since many years. In addition, Joachim was involved in the preparatory work for setting up a Unified Patent Court in Europe.

Noteworthy experience includes advising:

  • A pharmaceutical company concerning the infringement of an SPC by a generic product for the treatment of epilepsy.
  • Pfizer against a parallel importer to prevent parallel imports of a medicinal product from the EU accession countries during the paediatric extension of a supplementary protection certificate including proceedings in front of the CJEU.An innovative company of genetically engineered food additives on license agreements regarding the CRISPR technology.
  • A company in a patent dispute on offshore windparks in both patent infringement and nullity proceedings with regard to the German part of a European Patent.
  • A company producing industrial machines in the automotive industry in infringement and nullity proceedings concerning a German Patent.
  • A manufacturer of mounting machines for electronic components in a multinational patent dispute.
  • A global pharmaceutical company in a dispute on a license agreement on a bispecific antibody.

News & insights

Light trails in a city at night

News: 20 OCTOBER 2021

Trial win for A&O's U.S. IP Technology Disputes team

Allen & Overy’s U.S. IP Technology Disputes team recently achieved a complete victory for child car seat manufacturer Wonderland Group in an intellectual property (IP) trial against Evenflo. 

Read more
Blurred image of a fast moving train

News: 20 OCTOBER 2021

Allen & Overy advises Bridgepoint on the acquisition of a majority stake in PTV Group from Porsche SE

Allen & Overy has advised private equity house Bridgepoint on the acquisition of a majority stake in PTV Group ("PTV"), a leading global software company for traffic simulation and planning as well as…

Read more
Close up of an LCD circuit board

News: 15 OCTOBER 2021

Allen & Overy advises OEP’s Spanish portfolio company VASS on its merger with German IT consulting firm Ecenta AG

Allen & Overy has advised VASS Consultoría de Sistemas S.L., the Madrid-based portfolio company of US private equity investor One Equity Partners (OEP) which specialises in Customer Experience…

Read more
Front of car, lights blurring

Publications: 09 JULY 2021

German Federal Constitutional Court paves the way for the UPC

As an international treaty the Agreement on a Unified Patent Court (UPCA) provides for the establishment of the Unified Patent Court (UPC). As a joint Court of the Contracting Member States, the UPC…

Read more



Allen & Overy LLP
Maximilianstraße 35
80539 Munich

View office →



Admitted as German Rechtsanwalt, 1987


Docteur en droit, University of Geneva, Switzerland, 1987
Diplôme d’Etudes Supérieures en Droit, University of Geneva, Switzerland, 1984

Published work

  • J. Feldges, Das Nagoya- Protokoll und seine Umsetzung- Eine Bestandsaufnahme, in Festschrift für Sabine Rojahn, Die internationale Durchsetzung von Schutzrechten, München 2021, p. 5- 23;
  • J. Feldges, § 25 Schutz von Medizinprodukten durch technische Schutzrechte, in Erhard Anhalt, Peter Dieners, Handbuch des Medizinprodukterechts, 2nd Edition, 2017;
  • J. Feldges, B. Kramer (2011), “Intellectual Property in the Life Sciences”, Germany, pp. 193;
  • J. Feldges (2011), „Anmerkung zum Urteil des EuGH vom 18.10.2011 C-34/10
  • Brüstle/Greenpeace“, GRUR 2011, pp. 1045;
  • J. Feldges, B. Kramer (2010), „Die Bestimmung des Schutzbereiches von ergänzenden Schutzzertifikaten für Arzneimittel“, Festschrift für Wolfgang von Meibom, pp. 57;
  • J. Feldges (2009), „Kann die Dosierung eines Medikamentes Grundlage einer patentfähigen Erfindung sein?“ Festschrift für Thomas Reimann, pp. 91;
  • J. Feldges, B. Kramer (2009), “Patent Law, in Business Laws of Germany”, 2009 ed., p. 197-305;
  • J. Feldges (2007), „Die Durchsetzung von Patenten in europäischen Streitigkeiten“, Festschrift für Tilman Schilling, pp. 111;
  • J. Feldges, Kramer B. (2007), “Co-ownership of Patents under German Law, Journal of Intellectual Property Law & Practice”, pp. 742;
  • Kilger, Feldges, Jaenichen (2005), “The Erosion of Compound Protection In Germany”, Journal of the Patent and Trademark Office Society Vol. 87, pp. 569;
  • J. Feldges (2005), „Ende des absoluten Stoffschutzes? Zur Umsetzung der Biotechnologie-Richtlinie“, GRUR 2005, pp. 977.

Pro-bono experience

  • Joachim is since 2018 a curator for Amref Health Africa Germany and acted as an ambassador in A&O’s global charity partnership with Amref in 2014-2016.